Target intelligence / Profile preview

SH3 domain containing GRB2 like 2, endophilin A1 (SH3GL2)

Target
SH3GL2
Molecular classification
Adaptor protein, BAR domain protein, Signal transducing protein, Other (membrane-curvature protein involved in vesicle trafficking)
01

Overview

SH3 domain containing GRB2 like 2, endophilin A1 (SH3GL2) is an adaptor protein notable for its role in synaptic vesicle endocytosis, receptor trafficking, and membrane remodeling through its BAR domain, which senses and induces membrane curvature[1][2][4][13]. SH3GL2 is abundant in neuronal tissues, particularly the brain, and is essential for maintaining synaptic homeostasis, modulating autophagy in response to neuronal activity and calcium influx, and regulating protein quality control at synapses[3][5]. Mutations in SH3GL2 are associated with neurodegenerative risk, particularly Parkinson’s disease, where they impair synaptic autophagy induction. SH3GL2 also functions as a tumor suppressor in certain cancers, regulating apoptotic pathways and intracellular signaling networks[1][5].

Other names
Endophilin-A1Endophilin 1EEN-B1SH3 domain protein 2ASH3 domain-containing, GRB2-like protein 2SH3D2ACNSA2SH3P4SH3PA
02

Mechanism of action

Mechanisms inferred from protein function: regulation of membrane curvature and trafficking, modulation of synaptic vesicle endocytosis, impact on autophagy via calcium-sensitive conformational changes[3][4][5] Not directly targeted by approved drugs, as of current literature

03

Biological functions

Synaptic vesicle endocytosisReceptor traffickingApoptosisRegulation of autophagyNeurotrophin-dependent dendrite outgrowthNegative regulation of blood-brain barrier permeabilityNegative regulation of gene expression
04

Disease associations

Cancer (notably laryngeal squamous cell carcinoma, suggested as a tumor suppressor)Parkinson’s disease (mutation linked to increased disease risk and synaptic dysfunction)Neurodegenerative disease (implicated in synaptic homeostasis)Other (childhood pilocytic astrocytoma)
05

Safety considerations

No specific safety concerns documented for pharmacological targeting; primarily studied as a disease risk gene or pathway protein rather than a direct therapeutic intervention
06

Biomarkers

Parkinson’s disease–risk mutation in SH3GL2 has biomarker potential for genetic risk and synaptic dysfunction[3]Potential tumor suppressor gene biomarker in laryngeal squamous cell carcinoma[1]

Beyond the preview

Go deeper on SH3 domain containing GRB2 like 2, endophilin A1 (SH3GL2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SH3 domain containing GRB2 like 2, endophilin A1 (SH3GL2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call